Thomas Ichim is actually the lead scientist behind the

New Post Public Reply Private Reply Replies (1) Message Board
Meach patientgal #872

Thomas Ichim is actually the lead scientist behind the hemaxellerate program...  The most recent post quotes;

"On June 5, 2013 Regen  entered into an agreement with Oregon Health & Science University (“License Agreement”) whereby Oregon Health & Science University (“OHSU”)  granted to the Regen  an exclusive, worldwide, royalty bearing license to US patent No. 6,821,513 “Method for enhancing hematopoiesis” issued Nov. 23, 2004 (“Patent Rights”) and a non-exclusive, worldwide, royalty bearing license to, among other items, all inventions that are the subject of the invention disclosure giving rise to, or that are described in, patent applications included in the Patent Rights that do not issue into patents. (“Know-How”)."

Which is Thomas Ichim's domain.

alternatively...

I am quite certain Thomas Ichim is the head scientist of regen biopharma.

"SAN DIEGO, CA--(Marketwire - Jun 26, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today Thomas E. Ichim, PhD has joined the management team of its Regen BioPharma, Inc. subsidiary as Chief Scientific Officer and Director of Research. Regen BioPharma is the company's translational medicine platform for the rapid commercialization of stem cell therapies.

Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune.

David Koos, Chief Executive Officer of Bio-Matrix Scientific Group, stated: "Dr. Ichim is a seasoned biotechnology executive with a track record of scientific excellence. We now have a world-class team to lead our efforts to commercialize stem cell therapies."

(oh, the only reason for this post is to clarify what the last PR stated about hemaxellerate and Min)

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FirstEnergy Appoints Key Execs: Tech and Safety Push

Updated Category News Views 7

Well, ain't that a twist in the grid! FirstEnergy just reshuffled the deck, pulling in fresh senior blood to shake things up in safety, technology, and efficiency. It’s a bold move that should raise more than a few investor eyebrows. Meet the New Guards: Energizing FirstEnergy On the helm of this ambitious push, you have Chris Beam, Hanneke Counts, and Daniel Puscas...

Continue Reading
Axos Clearing Teams Up with Envestnet for Enhanced Solutions

Updated Category News Views 129

Axos Clearing Partners with Envestnet Axos Clearing, a subsidiary of Axos Financial Inc. (NYSE: AX), has recently formed an exciting strategic partnership with Envestnet, a leading provider of integrated technology and wealth solutions. This collaboration promises to deliver cutting-edge managed account solutions directly into Axos Clearing's Axos Complete portal,...

Continue Reading
Foresight Group Holdings Undertakes Strategic Share Buyback Initiative

Updated Category News Views 165

Foresight Group's Share Buyback Program Overview Foresight Group Holdings Limited, renowned for its expertise in managing investments in real assets, has initiated a strategic share buyback program. This program, first announced in early April, reflects the Group's commitment to optimizing shareholder value while enhancing its financial positioning within the market....

Continue Reading
Goldman Sachs Predicts Modest 2025 Gains for European Market

Updated Category News Views 153

Goldman Sachs' Outlook for European Equities Goldman Sachs analysts anticipate modest returns for the STOXX Europe 600 index in the coming years, projecting a 4% price increase and a total return of about 7% when accounting for dividends. This cautious viewpoint suggests a target price of 530 for the index, rising from its current standing of 511. Growth Expectations and...

Continue Reading
How Year-Round Holiday Shopping Is Transforming Retail

Updated Category News Views 197

Retailers Adapt to Year-Round Holiday Shopping Trends Embracing the holiday spirit well beyond the traditional December confines, retailers are rapidly evolving their strategies. Companies are now recognizing the changing mindset of consumers who enjoy anticipating the holidays much earlier than before. From themed decorations popping up during summer to the concept of...

Continue Reading